The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Discover the best Black Friday deals, Fort Wayne's ranking as a top retirement spot, and Walmart's pullback on diversity policies.

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...